Body Weight

• “Fat cells may absorb and break down common chemotherapy drugs, reducing their potency…This finding may help explain why obesity is linked to poorer outcomes in several types of cancer.”¹Obesity and cancer: Increasing risks, complicating treatments. Cancer Treatment Centers of America. February 8, 2021. Viewed September 21, 2021.
• Lower cancer-specific mortality among older females with cancer as a whole eating a diet with the highest adherence to World Cancer Research Fund/American Institute for Cancer Research guidelines compared to the lowest in a large observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study²Inoue-Choi M, Robien K, Lazovich D. Adherence to the WCRF/AICR guidelines for cancer prevention is associated with lower mortality among older female cancer survivors. Cancer Epidemiology, Biomarkers & Prevention. 2013 May;22(5):792-802.

• Earlier cancer relapse (shorter time to progression) among people with metastatic colorectal cancer with fatigue and weight loss related to chemotherapy compared to those without fatigue and weight loss in a mid-sized observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study³Innominato PF, Giacchetti S et al. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer. 2013 Jul 15;119(14):2564-73.

• Shorter survival among people with high-grade glioma who were either underweight (BMI less than 18.5) or obese (BMI more than 30) compared to normal BMI (between 18.5 and 29.9) during 1-5 years prior to the study interview in a large observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study⁴Siegel EM, Nabors LB et al. Prediagnostic body weight and survival in high grade glioma. Journal of Neuro-oncology. 2013 Aug;114(1):79-84.
• A link between increasing BMI and worse survival among people with high-grade glioma in a mid-sized observational study⁵Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC. Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma. Journal of Neuro-oncology. 2012 Jan;106(2):383-9.

• No link between mortality from breast cancer diagnosed before menopause and body mass index (BMI) in a very large meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 126 observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies⁶Chan DSM, Abar L et al. World Cancer Research Fund International: Continuous Update Project-systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. Cancer Causes & Control. 2019 Nov;30(11):1183-1200.
• Lowest risk of overall mortality among women with breast cancer who kept their weight stable in the first few years after diagnosis, while more than 10% weight gain or loss was linked to higher mortality; excessive weight loss after diagnosis of breast cancer, especially in patients with other chronic illnesses such as cardiovascular disease, was associated with reduced overall survival—patients were more likely to die from one of the other chronic illnesses than from cancer in a very large observational study⁷Caan BJ, Kwan ML et al. Weight change and survival after breast cancer in the After Breast Cancer Pooling Project. Cancer Epidemiology, Biomarkers & Prevention. 2012 Aug;21(8):1260-71.
• 13% increase in breast cancer-specific mortality with each 5 BMI units, such as a BMI change from 25 to 30, of weight gain after diagnosis⁸Nichols HB, Trentham-Dietz A et al. Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiology, Biomarkers & Prevention. 2009 May;18(5):1403-9.
• Weak effects on a marker of proliferation (Ki-67) after tumor biopsy among nondiabetic women treated with 850 mg metformin twice per day compared to placebo, with different outcomes among women with higher body mass index or waist/hip girth-ratio compared to lower measures in a mid-sized RCT⁹Bonanni B, Puntoni M et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012 Jul 20;30(21):2593-600.

Our commentary: If you find these results confusing, you’re not alone. Researchers are still trying to figure out the “obesity paradox” among breast cancer survivors. What the evidence shows us so far is this:

1. People with postmenopausal breast cancer who are obese have a worse prognosis.
2. Substantial weight gain after diagnosis is linked with a worse prognosis.
3. Excessive weight loss—more than 10% of your body weight—after diagnosis is linked to higher overall mortality, but mostly from other conditions and not from breast cancer. You will need to evaluate with your doctor your own risks of breast cancer recurrence or relapse, cardiovascular disease, diabetes, and other conditions, based on your body weight, personal health history, family history, metabolic status, and other factors for each disease. Discuss what your biggest risks are and how to manage them. 
4. Modest weight loss—up to 10% of your body weight—is not a concern and could be very beneficial in reducing metabolic and other factors contributing to worse outcomes (see Optimizing your body terrain below.)

• Poorer prognosis among people with colorectal cancer who are obese in a large meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 16 observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies¹⁰Lee J, Meyerhardt JA, Giovannucci E, Jeon JY. Association between body mass index and prognosis of colorectal cancer: a meta-analysis of prospective cohort studies. PLoS One. 2015 Mar 26;10(3):e0120706.
• No link between short-term survival and body weight among people undergoing chemotherapy for colon cancer; neither body weight nor weight gain during treatment was linked to any change in survival over the next three years or so in a large observational study¹¹Lee DW, Cho S, Shin A, Han SW, Kim TY. Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial. Scientific Reports. 2020 Nov 10;10(1):19467.
• 45% higher mortality among people with stage 4 colorectal cancer who were obese in the decade before their initial diagnosis compared to normal prediagnosis body mass index in a mid-sized observational study¹²Davis JS, Chavez JC et al. Association of prediagnosis obesity and postdiagnosis aspirin with survival from stage IV colorectal cancer. JAMA Network Open. 2022 Oct 3;5(10):e2236357.

• 28% higher cancer-specific mortality among men with nonmetastatic prostate cancer with postdiagnosis obesity (BMI 30 or higher) compared to healthy weight (BMI of 18.5 to 24.9), and even higher cancer-specific mortality among men gaining weight after diagnosis in a very large observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study¹³Troeschel AN, Hartman TJ et al. Postdiagnosis body mass index, weight change, and mortality from prostate cancer, cardiovascular disease, and all causes among survivors of nonmetastatic prostate cancer. Journal of Clinical Oncology. 2020 Jun 20;38(18):2018-2027.

• No evidence of an effect of body weight on histological features, ATA risk of recurrence, activity of 131I administered and prevalence of 131I avid metastatic disease after first 131I treatment after treatment with total thyroidectomy among people with differentiated thyroid cancer in a large observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study¹⁴Matrone A, Ceccarini G et al. Potential impact of BMI on the aggressiveness of presentation and clinical outcome of differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 2020;105(4):dgz312.
• No evidence of an effect of body weight on clinical response to therapy, histopathologic features, risk of recurrence, cumulative dose of RAI ablation, and prevalence of 131I avid metastatic disease during an average 3.4 year follow-up among people with differentiated thyroid cancer in a mid-sized observational study¹⁵Elbasan O, Yavuz DG. Effects of concomitant obesity and diabetes on the aggressiveness and outcomes of differentiated thyroid cancer patients. Archives of Endocrinology and Metabolism. 2021;65(4):455-461.
• More aggressive cancer at diagnosis for papillary thyroid cancer among obese people compared to nonobese people, but no evidence of an effect of body weight on response to radioactive iodine (RAI) therapy in a mid-sized observational study¹⁶Cao J, Zhu X et al. Potential impact of body mass index on the clinical outcome of papillary thyroid cancer after high-dose radioactive iodine therapy. Frontiers in Endocrinology (Lausanne). 2022;13:870530.

Modest evidence of better survival and lower risk of recurrence among people with high-risk positive stage 1–3 breast cancer but otherwise healthy with the highest scores for following a healthy lifestyle regarding physical activity; body weight; eating more fruits and vegetables and less red and processed meat or sugar-sweetened beverages; and low or no smoking or use of alcohol

• 58% lower mortality and 37% lower risk of recurrence during about 7 years of follow up among people with high-risk positive stage 1–3 breast cancer but otherwise healthy with the highest scores for following a healthy lifestyle regarding physical activity; body weight; eating more fruits and vegetables and less red and processed meat or sugar-sweetened beverages; and low or no smoking or use of alcohol compared with the lowest scores in a large observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study¹⁷Cannioto RA, Attwood KM et al. Adherence to cancer prevention lifestyle recommendations before, during, and 2 years after treatment for high-risk breast cancer. JAMA Network Open. 2023 May 1;6(5):e2311673.

Good evidence of lower risk of lethal prostate cancer, but not overall prostate cancer, among people following a healthy lifestyle including maintaining a body weight under 30 BMI

• 45% lower risk of lethal prostate cancer, but not overall prostate cancer, over 27 years among people with high genetic risk following a healthy lifestyle of a healthy weight, vigorous physical activity, no smoking, and a healthy diet compared to an unhealthy lifestyle in a very large observational study¹⁸Plym A, Zhang Y et al. A healthy lifestyle in men at increased genetic risk for prostate cancer. European Urology. 2022 May 27:S0302-2838(22)02342-9.
• 68% lower risk of lethal prostate cancer among men observing 5 or 6 of these lifestyle behaviors compared to 0 or 1 behavior in a very large observational study:¹⁹Kenfield SA, Batista JL et al. Development and application of a lifestyle score for prevention of lethal prostate cancer. Journal of the National Cancer Institute. 2015 Nov 17;108(3):djv329.
  • Not currently smoking or quit 10 or more years ago
  • Body mass index under 30 kg/m2
  • High vigorous physical activity
  • High intake of tomatoes
  • High intake of fatty fish
  • Low intake of processed meat

Metabolic syndrome, either with or without inflammation: moderate evidence of higher risk of cancer as a whole and several types of cancer among people with the highest scores for metabolic syndrome, indicating excess body fat around the waist and at least 2 of the following: high blood pressure, high blood sugar or a diabetes diagnosis, abnormal cholesterol, and high triglyceride levels, with higher risks if inflammation was also present

• Higher risk of cancer (27% higher risk of cancer as a whole, 211% higher risk of breast cancer, 333% higher risk of endometrial cancer, 452% higher risk of kidney cancer, 254% higher risk of colorectal cancer, 161% higher risk of liver cancer) among people with the highest scores for metabolic syndrome, indicating excess body fat around the waist and at least 2 of the following and rising over a 4-year period, compared to the lowest scores in a very large observational study:²⁰Deng L, Liu T et al. The association of metabolic syndrome scores trajectory patterns with risk of all cancer types. Cancer. 2024 Mar 11.
  • High blood pressure
  • High blood sugar or a diabetes diagnosis
  • Abnormal cholesterol and
  • High triglyceride levels

  Many of these increased risks were even higher among people with a higher marker of inflammation (C-reactive protein) compared to a lower marker.

• Substantially better survival among people with metastatic melanoma who are obese and receiving targeted therapy or immunotherapy, but not chemotherapy, compared to people of normal weight in a large observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study²¹McQuade JL, Daniel CR et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncology. 2018;19(3):310-322.
• Better overall survival with increasing body weight among people with advanced non-small cell lung cancer treated with immunotherapy (atezolizumab), but not those treated with chemotherapy (docetaxel) in a large observational study²²Kichenadasse G, Miners JO et al. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncology. 2020 Apr 1;6(4):512-518.
• Better response to treatment, progression-free survival, and overall survival among overweight or obese people with advanced non-small cell lung cancer, melanoma, renal cell carcinoma, and other types of advanced cancer treated with anti-PD-1/PD-L1 inhibitors in a mid-sized observational study²³Cortellini A, Bersanelli M et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. Journal of ImmunoTherapy of Cancer. 2019;7(1):57.

Is this survival advantage, called the obesity paradox, due to immunotherapy’s action against targets more common in cancers linked to obesity? Researchers are trying to answer this and other questions:

• Is the survival advantage more related to having been obese for a long time or for a short term?
• Did obesity contribute to the development of a subtype of cancer with the targets that immunotherapy works against?
• Is obesity driving the advantage in survival, or do obese patients tend to have a cancer that happens to have a target against which the immunotherapy is effective?

Preliminary (conflicting) evidence of better survival among people with glioblastoma multiforme who were overweight or obese; opposite impacts of body weight are seen with high-grade glioma as noted above

• No evidence of a link between risk of glioblastoma multiforme or survival after diagnosis in a large observational study²⁴Barami K, Lyon L, Conell C. Type 2 diabetes mellitus and glioblastoma multiforme—assessing risk and survival: results of a large retrospective study and systematic review of the literature. World Neurosurgery. 2017 Oct;106:300-307.
• Better survival among people with glioblastoma multiforme who were overweight or obese compared to normal weight in a mid-sized observational study²⁵Potharaju M, Mangaleswaran B et al. Body mass index as a prognostic marker in glioblastoma multiforme: a clinical outcome. International Journal of Radiation Oncology, Biology, Physics. 2018 Sep 1;102(1):204-209.

Until we know some of these answers, we cannot encourage you to gain weight to improve your survival. Also note that improved survival with more body weight has been found mainly among people with advanced cancer.

The connections among obesity, uncontrolled blood sugar, and insulin resistance are widely accepted in conventional medicine. Obesity is “the major risk factor of type 2 diabetes,” and after a diabetes diagnosis, “mortality rates were superior for patients with normal weight.”²⁶Chobot A, Górowska-Kowolik K, Sokołowska M, Jarosz-Chobot P. Obesity and diabetes—not only a simple link between two epidemics. Diabetes/Metabolism Research and Reviews. 2018 Oct;34(7):e3042.

Modest evidence of better blood sugar and insulin sensitivity among people losing weight

Preliminary evidence of more weight loss among obese people who reduced high blood sugar levels

• Lower markers of insulin resistance, with a weak trendan apparent change due to a therapy, close to but not achieving full statistical significance (this is the CancerChoices definition; other researchers and studies may define this differently toward lower fasting glucose, among children who were obese who lost weight in a large meta-regression of intervention studies²⁷Matson RI, Perry R et al. Change in obesity-related metabolic abnormalities associated with body mass index improvement through life-style intervention: a meta-regression. Pediatric Diabetes. 2020 Mar;21(2):173-193.
• Higher risk of developing insulin resistance and type 2 diabetes among people who are obese compared to people of normal weight in reviews of studies²⁸Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006 Dec 14;444(7121):840-6; Kahn BB, Flier JS. Obesity and insulin resistance. Journal of Clinical Investigation. 2000 Aug;106(4):473-81.
• Lower levels of adiponectin, a protein linked to better insulin sensitivity, among people who are obese compared to people of normal weight in a review of studies²⁹Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obesity Reviews. 2005 Feb;6(1):13-21.
• Better insulin sensitivity and lower HOMA-IR levels among young adult women who were overweight or obese and reduced their body weight compared to matched controls, women who relapsed to overweight or obesity, or their matched controls in a small observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study³⁰Clamp LD, Hume DJ, Lambert EV, Kroff J. Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history. Nutrition & Diabetes. 2017 Jun 19;7(6):e282.
• More weight loss among obese people participating in a weight-loss program of diet, education, and moderate exercise who reduced high blood sugar (hyperglycemia) compared to people with persistent high blood sugar in a small observational study³¹Zalejska-Fiolka J, Birková A et al. Successful correction of hyperglycemia is critical for weight loss and a decrease in cardiovascular risk in obese patients. Journal of Nutritional Biochemistry. 2022 Aug;106:109021.

The connection between obesity and hormone imbalance is widely accepted in conventional medicine. “Fat cells have a tendency to produce high levels of estrogen that may increase the risk of breast and gynecologic cancers.”³²Obesity and cancer: Increasing risks, complicating treatments. Cancer Treatment Centers of America. February 8, 2021. Viewed September 21, 2021.

Obesity-related immune cell infiltration, along with inflammation and increased oxidative stress, promote metabolic impairments in insulin-sensitive tissues, leading eventually to insulin resistance, organ failure, and premature aging.³³Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Frontiers in Immunology. 2020 Jul 22;11:1582.

During obesity, the insulin signaling pathway is deregulated, establishing a state of low-grade systemic inflammation.³⁴Ieronymaki E, Daskalaki MG, Lyroni K, Tsatsanis C. Insulin signaling and insulin resistance facilitate trained immunity in macrophages through metabolic and epigenetic changes. Frontiers in Immunology. 2019 Jun 12;10:1330. As the main inducer of systemic low-level inflammation, obesity is a main risk factor for type 2 diabetes. Obesity-related inflammation, along with immune cell infiltration and increased oxidative stress, promote metabolic impairments in insulin-sensitive tissues, leading eventually to insulin resistance, organ failure, and premature aging.³⁵Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Frontiers in Immunology. 2020 Jul 22;11:1582.

Good evidence of a link between obesity and inflammation

Modest evidence of less inflammation among people losing excess weight

• Low-grade chronic inflammatory state among people who are obese compared to people of normal weight in a review of 19 studies rated as excellent quality³⁶Battineni G, Sagaro GG et al. Impact of obesity-induced inflammation on cardiovascular diseases (CVD). International Journal of Molecular Sciences. 2021 Apr 30;22(9):4798.
• Lower marker of inflammation (C-reactive protein) among children who were obese with weight loss compared to baseline in a meta-regression of 68 intervention studies³⁷Matson RI, Perry R et al. Change in obesity-related metabolic abnormalities associated with body mass index improvement through life-style intervention: a meta-regression. Pediatric Diabetes. 2020 Mar;21(2):173-193.

Obesity induces oxidative stress.³⁸Ieronymaki E, Daskalaki MG, Lyroni K, Tsatsanis C. Insulin signaling and insulin resistance facilitate trained immunity in macrophages through metabolic and epigenetic changes. Frontiers in Immunology. 2019 Jun 12;10:1330. This increased oxidative stress, along with immune cell infiltration and inflammation, promote metabolic impairments in insulin-sensitive tissues, leading eventually to insulin resistance, organ failure, and premature aging.³⁹Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Frontiers in Immunology. 2020 Jul 22;11:1582.

Obesity is linked to lower microbial diversity.⁴⁰Gérard C, Vidal H. Impact of Gut Microbiota on Host Glycemic Control. Frontiers in Endocrinology (Lausanne). 2019 Jan 30;10:29.

• A change in the ratio of some microbes, with fewer beneficial microbes and more harmful ones, with weight gain beyond a normal body weight, and then a reversal in the ratio with weight loss, in a review of studies⁴¹Mathur R, Barlow GM. Obesity and the microbiome. Expert Review of Gastroenterology & Hepatology. 2015 Jun;9(8):1087-1099.
• Changes in the composition of the intestinal microbiota linked to obesity in a review⁴²Hartstra AV, Bouter KE, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015 Jan;38(1):159-65.
• Partial reversal of obesity-associated microbial and metabolic changes with weight loss among both humans and mice who are obese in a review of studies⁴³Liu R, Hong et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nature Medicine. 2017 Jul;23(7):859-868.

Some research shows that categorizing individuals according to 2 microbial enterotypes (dominance of either Prevotella or Bacteroides) may be useful in predicting responses to diets and drugs. Knowing your enterotype could help in personalizing obesity management.⁴⁴Christensen L, Roager HM, Astrup A, Hjorth MF. Microbial enterotypes in personalized nutrition and obesity management. American Journal of Clinical Nutrition. 2018 Oct 1;108(4):645-651.

• Higher risk of low vitamin D levels among people with high body mass index compared to other people in a meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 4 observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies⁴⁵Xu J, Yuan X et al. Association of circulating 25-hydroxyvitamin D levels with colorectal cancer: an updated meta-analysis. Journal of Nutritional Science and Vitaminology (Tokyo). 2018;64(6):432-444.

Longer chromosomal telomeres are strongly linked to longer survival.⁴⁶von Zglinicki T, Saretzki G, Passos J. Aging and telomeres. Reference Module in Biomedical Sciences. Elsevier. 2014.

Good evidence of a link between telomere length and body mass index

• Shorter telomere length, especially in younger individuals, among people with higher body mass index (BMI) in a very large meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 87 observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies⁴⁷Gielen M, Hageman GJ et al; TELOMAAS group. Body mass index is negatively associated with telomere length: a collaborative cross-sectional meta-analysis of 87 observational studies. American Journal of Clinical Nutrition. 2018 Sep 1;108(3):453-475.

• Bigger improvements in scores in five cognitive domains among postmenopausal women with breast cancer and not taking metformin with the highest baseline BMIs participating in a weight-loss intervention compared to no intervention and compared to lower baseline BMIs in a mid-sized RCTrandomized controlled trial, a study design in which people are randomly assigned to either an experimental group or a control group to compare the outcomes from different treatments; an RCT is considered a strong design for determining a therapy’s effects⁴⁸Hartman SJ, Nelson SH et al. The effects of weight loss and metformin on cognition among breast cancer survivors: evidence from the Reach for Health study. Psycho-Oncology. 2019 Aug;28(8):1640-1646.

• Moderately higher risk of hot flashes among women with breast cancer who gained at least 10% of their prediagnosis weight in the 2 years after diagnosis compared to women keeping a stable weight, and a weak trend toward lower risk of hot flashes among women losing at least 10% of prediagnosis weight compared to stable weight in a large observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study⁴⁹Caan BJ, Emond JA et al. Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. Journal of Clinical Oncology. 2012 May 1;30(13):1492-7.

• Higher risk of treatment-related lymphedema among people with breast cancer who are obese compared to normal-weight survivors in a review of 60 clinical studies⁵⁰Paskett ED, Dean JA, Oliveri JM, Harrop JP. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. Journal of Clinical Oncology. 2012 Oct 20;30(30):3726-33.

Surgery outcomes:

Good evidence of longer surgery times, higher illness (morbidity) after surgery, and higher rates of conversion from laparoscopic to open surgery among people who are obese

• Longer surgery time, more blood loss, and higher incidence of intra-abdominal infection during stomach cancer surgery among people who are obese compared to other people in a mid-sized observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study⁵¹Kodera Y, Ito S et al. Obesity and outcome of distal gastrectomy with D2 lymphadenectomy for carcinoma. Hepatogastroenterology. 2004 Jul-Aug;51(58):1225-8.
• Higher conversion from laparoscopic to open surgery, longer laparoscopic colorectal surgery time, and higher morbiditya state of being unhealthy due a particular disease or situation after surgery among people who are obese compared to others in a meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 8 observational studies⁵²Zhou Y, Wu L, Li X, Wu X, Li B. Outcome of laparoscopic colorectal surgery in obese and nonobese patients: a meta-analysis. Surgical Endoscopy. 2012 Mar;26(3):783-9.
• Substantially longer surgery time and higher rates of conversion from laparoscopic colorectal surgery to open surgery, higher morbidity, more surgical site infection, and more anastomotic leakage among people with more visceral fat compared to other people in a meta-analysis of 4 observational studies⁵³Yang T, Wei M, He Y, Deng X, Wang Z. Impact of visceral obesity on outcomes of laparoscopic colorectal surgery: a meta-analysis. ANZ Journal of Surgery. 2015 Jul-Aug;85(7-8):507-13.
• Longer surgery time and greater blood loss during radical prostatectomy among people with obesity (BMI of 30 or higher) compared to other people in a mid-sized observational study⁵⁴Lindner U, Lawrentschuk N, Abouassaly R, Fleshner NE, Trachtenberg J. Radical prostatectomy in obese patients: improved surgical outcomes in recent years. International Journal of Urology. 2010 Aug;17(8):727-32.

Good evidence of higher risk of infection and other complications related to surgery among people who are obese

Modest evidence of higher risk of surgical site infection among people who are obese

• Higher risks of wound infection after esophageal surgery among people with excess body weight compared to people of normal weight in a large meta-analysis of 19 studies⁵⁵Gao H, Feng HM et al. Impact of high body mass index on surgical outcomes and long-term survival among patients undergoing esophagectomy: a meta-analysis. Medicine (Baltimore). 2018 Jul;97(28):e11091.
• Three times the risk of complications and blood transfusions during surgery, plus greater risk of incontinence after surgery, among men treated with radical prostatectomy for prostate cancer with obesity compared to normal body weight in a mid-sized observational study⁵⁶Gucci M, Sebastianelli A et al. Role of abdominal obesity for functional outcomes and complications in men treated with radical prostatectomy for prostate cancer: results of the Multicenter Italian Report on Radical Prostatectomy (MIRROR) study. Scandinavian Journal of Urology. 2014 Apr;48(2):138-45.
• Higher risk of sternal wound infection during bilateral internal mammary artery grafting among people who are obese compared to other people in a mid-sized observational study⁵⁷He GW, Ryan WH, Acuff TE, Bowman RT, Douthit MB, Yang CQ, Mack MJ. Risk factors for operative mortality and sternal wound infection in bilateral internal mammary artery grafting. Journal of Thoracic and Cardiovascular Surgery. 1994 Jan;107(1):196-202.
• Higher risk of surgical site infection among people who are obese in a large observational study⁵⁸Barber GR, Miransky J et al. Direct observations of surgical wound infections at a comprehensive cancer center. Archives of Surgery 1995;130(10):1042-7.

Good evidence of higher risks of cardiovascular complications after surgery among people with excess body weight

• Higher risks of cardiovascular complications after esophageal surgery among people with excess body weight compared to people of normal weight in a large meta-analysis of 19 studies⁵⁹Gao H, Feng HM et al. Impact of high body mass index on surgical outcomes and long-term survival among patients undergoing esophagectomy: a meta-analysis. Medicine (Baltimore). 2018 Jul;97(28):e11091.

Good evidence of substantially higher risk of blood clots after surgery among women with body mass index (BMI) of 25 or higher

• Substantially higher risk of blood clots after surgery among women with body mass index (BMI) of 25 or higher, and increasing risk as BMI increased, compared to BMI less than 25 in a very large observational study⁶⁰Parkin L, Sweetland S et al. Million Women Study Collaborators. Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study. Circulation 2012;125:1897–904.

Anxiety: good evidence of a link between obesity and anxiety (not specific to cancer)

• A link between greater anxiety and obesity in a meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 16 observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies not specific to cancer⁶¹Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. International Journal of Obesity (London). 2010 Mar;34(3):407-19.
• Increased frequency of anxiety among people with increasing body weight in meta-analysis of 25 observational studies not specific to cancer⁶²Amiri S, Behnezhad S. Obesity and anxiety symptoms: a systematic review and meta-analysis. Neuropsychiatrie. 2019 Jun;33(2):72-89. English.

Depression:

Preliminary evidencesignificant effects in small or poorly designed clinical studies OR conflicting results in adequate studies but a preponderance of evidence of an effect (this is the CancerChoices definition; other researchers and studies may define this differently) of a link between a large waist-to-hip ratio and depression among middle-aged women (not specific to cancer)

• Higher incidence of a large waist-to-hip ratio among middle-aged women with higher levels of depression compared to others in a mid-sized observational study⁶³Wing RR, Matthews KA, Kuller LH, Meilahn EN, Plantinga P. Waist to hip ratio in middle-aged women. Associations with behavioral and psychosocial factors and with changes in cardiovascular risk factors. Arteriosclerosis and Thrombosis. 1991 Sep-Oct;11(5):1250-7.

Modest evidence of fewer self-reported symptoms of depression among people with symptoms participating in calorie restriction, behavioral therapy, and exercise leading to 30 pounds or more of weight loss

• Fewer self-reported symptoms of depression among people with symptoms eating a very low-calorie diet (VLCD) for longer than 7 weeks, participating in behavioral therapy, and low-intensity exercise, and losing 14.1 kg (31 pounds) or more compared to any of these interventions alone in a meta-analysis of 9 clinical studies⁶⁴Ein N, Armstrong B, Vickers K. The effect of a very low calorie diet on subjective depressive symptoms and anxiety: meta-analysis and systematic review. International Journal of Obesity (London). 2019 Jul;43(7):1444-1455.

Hot flashes: modest evidence of fewer hot flashes among overweight or obese women reducing body weight

• Moderately fewer bothersome hot flashes among overweight or obese women with urinary incontinence reducing body weight, body mass index or abdominal circumference after participating in an intensive behavioral weight loss program compared to controls in a structured health education program in a mid-sized RCTrandomized controlled trial, a study design in which people are randomly assigned to either an experimental group or a control group to compare the outcomes from different treatments; an RCT is considered a strong design for determining a therapy’s effects⁶⁵Huang AJ, Subak LL et al; Program to Reduce Incontinence by Diet and Exercise Investigators. An intensive behavioral weight loss intervention and hot flushes in women. Archives in Internal Medicine. 2010 Jul 12;170(13):1161-7.
• Substantially fewer hot flashes among overweight or obese women with 4 or more hot flashes per day participating in a weight-loss intervention compared to wait-list controls, with reductions in weight and hot flashes significantly correlated in a small RCT⁶⁶Thurston RC, Ewing LJ, Low CA, Christie AJ, Levine MD. Behavioral weight loss for the management of menopausal hot flashes: a pilot study. Menopause. 2015 Jan;22(1):59-65.

Pain: modest evidence of higher risk of pain (not specific to cancer) among people with obesity and less pain among those losing weight

Obesity is a risk factor for chronic pain.⁶⁷Totsch SK, Waite ME, Sorge RE. Dietary influence on pain via the immune system. Progress in Molecular Biology and Translational Science. 2015;131:435-69.

• Higher risk of pain among people who experience overweight/obesity early in life compared to other people, and treatments for obesity reduce pain secondary to weight loss in a review of observational studies⁶⁸Janke EA, Collins A, Kozak AT. Overview of the relationship between pain and obesity: What do we know? Where do we go next? Journal of Rehabilitation Research & Development. 2007;44(2):245-62.
• More weight loss and less pain among people with knee osteoarthritis participating in an intensive low-energy diet maintained by frequent consultations with a dietician compared to minimal attention in a small RCT⁶⁹Bliddal H, Leeds AR, Stigsgaard L, Astrup A, Christensen R. Weight loss as treatment for knee osteoarthritis symptoms in obese patients: 1-year results from a randomised controlled trial. Annals of the Rheumatic Diseases. 2011 Oct;70(10):1798-803.
• Higher risk of chronic pain among elderly obese people (BMI 30–34.9) and four times the risk among severely obese people (BMI≥35) compared to elderly people of normal weight (BMI 18.5–24.9) in a mid-sized observational study⁷⁰McCarthy LH, Bigal ME, Katz M, Derby C, Lipton RB. Chronic pain and obesity in the elderly: results from the Einstein aging study. Journal of the American Geriatrics Society. 2009 Jan;57(1):115-9.
• Substantially higher risk of pain among people with central obesity compared to other people in a mid-sized observational study⁷¹Ray L, Lipton RB, Zimmerman ME, Katz MJ, Derby CA. Mechanisms of association between obesity and chronic pain in the elderly. Pain. 2011 Jan;152(1):53-59.

Sleep disruption: preliminary evidence of lower sleep disturbance scores among sedentary obese or overweight people losing weight or abdominal fat

• Lower sleep disturbance scores among sedentary obese or overweight people losing weight or abdominal fat compared to no loss in a small observational study⁷²Nam S, Stewart KJ, Dobrosielski DA. Lifestyle intervention for sleep disturbances among overweight or obese individuals. Behavioral Sleep Medicine. 2016;14(3):343-50.

Stress: no evidence of an effectoverall, one or more studies did not demonstrate that a treatment or intervention led to an expected outcome; this does not always mean that there is no effect in clinical practice, but that the studies may have been underpowered (too few participants) or poorly designed. Larger, well-designed studies provide more confidence in making assessments. of moderate weight loss (about 8 pounds) on self-reported stress among adults with excess weight or obesity in a combined analysis of studies (not specific to cancer)

• No effect on self-reported stress with diet-induced weight loss averaging about 8 pounds among adults with excess weight or obesity compared to those who did not lose weight in a meta-analysis of 10 RCTs⁷³Booth AO, Wang X, Turner AI, Nowson CA, Torres SJ. Diet-induced weight loss has no effect on psychological stress in overweight and obese adults: a meta-analysis of randomized controlled trials. Nutrients. 2018 May 14;10(5):613.

• 17% higher risk of breast cancer diagnosis after menopause with each 5 BMI units, such as a BMI change from 25 to 30 of adult weight gain in a very large meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 126 observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies⁷⁵Chan DSM, Abar L et al. World Cancer Research Fund International: Continuous Update Project-systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. Cancer Causes & Control. 2019 Nov;30(11):1183-1200.
• 14% higher risk of a breast cancer diagnosis among postmenopausal white women genetically predisposed to breast cancer with body mass index (BMI) of 25 or higher in a large observational study⁷⁶Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
• Higher risk of breast cancer with larger waist circumferences (14 studies) or waist-to-hip ratio (15 studies) among postmenopausal women, but not premenopausal women, in a meta-analysis of observational studies⁷⁷Chen GC, Chen SJ et al. Central obesity and risks of pre- and postmenopausal breast cancer: a dose-response meta-analysis of prospective studies. Obesity Reviews. 2016 Nov;17(11):1167-1177.
• A moderately higher risk of breast cancer with larger waist-to-hip ratio among women, with a slightly higher risk with premenopausal women compared to postmenopausal women in a meta-analysis of observational studies⁷⁸Connolly BS, Barnett C, Vogt KN, Li T, Stone J, Boyd NF. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutrition and Cancer. 2002;44(2):127-38.
• Lower risk of breast cancer with weight loss in a very large meta-analysis of 139 observational studies⁷⁹Hardefeldt PJ, Penninkilampi R, Edirimanne S, Eslick GD. Physical activity and weight loss reduce the risk of breast cancer: a meta-analysis of 139 prospective and retrospective studies. Clinical Breast Cancer. 2018 Aug;18(4):e601-e612. Our note: We assume weight loss is beneficial if you’re overweight at baseline.
• 10–15% lower risk of breast cancer—both before and after menopause—with adult weight loss in a very large meta-analysis of 126 observational studies⁸⁰Chan DSM, Abar L et al. World Cancer Research Fund International: Continuous Update Project-systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. Cancer Causes & Control. 2019 Nov;30(11):1183-1200.
• Higher risk of second primary cancers among people with breast cancer with higher BMI in a large observational study⁸¹Feigelson HS, Bodelon C, Powers JD et al. Body mass index and risk of second cancer among women with breast cancer. Journal of the National Cancer Institute. 2021 Apr 5:djab053.
• 14% lower risk of premenopausal breast cancer with each increase of 5 BMI units, such as a BMI change from 25 to 30, among women aged 18–30, but adult weight gain and greater overweight or obesity increased breast cancer risk in postmenopausal women, but only for HR+ but not HR- breast cancers ia very large meta-analysis of 126 observational studies⁸²Chan DSM, Abar L et al. World Cancer Research Fund International: Continuous Update Project-systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. Cancer Causes & Control. 2019 Nov;30(11):1183-1200.
• 18% lower risk of breast cancer among women 50 years and older not using postmenopausal hormones with weight loss of more than 4.4 pounds (2 kilograms), increasing to 32% lower risk among women losing 20 pounds (9 kilograms), sustained over approximately 10 years or more in a large observational study⁸³Teras LR, Patel AV et al. Sustained weight loss and risk of breast cancer in women ≥50 years: a pooled analysis of prospective data. Journal of the National Cancer Institute. 2019;djz226.

• 18% higher risk of colon cancer among young adults who are overweight or obese compared with those with normal weight, but less association among women and rectal cancer, in a very large meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 15 observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies⁸⁴Lei X, Song S, Li X, Geng C, Wang C. Excessive body fat at a young age increases the risk of colorectal cancer: a systematic review and meta-analysis. Nutrition and Cancer. 2021;73(9):1601-1612.
• 23-59% higher risk of colorectal cancer (depending on the specific site) with higher body mass index (BMI) in a meta-analysis of 30 observational studies⁸⁵Robsahm TE, Aagnes B et al. Body mass index, physical activity, and colorectal cancer by anatomical subsites: a systematic review and meta-analysis of cohort studies. European Journal of Cancer Prevention. 2013 Nov;22(6):492-505.
• 20% higher risk of colorectal cancer among people with obesity compared with people without obesity in a meta-analysis of 103 observational studies⁸⁶Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. International Journal of Cancer. 2009 Jul 1;125(1):171-80.
• 40% higher risk of colorectal serrated polyps among people with the highest category body mass index (BMI) compared to the lowest in a meta-analysis of observational or interventional studies⁸⁷Bailie L, Loughrey MB, Coleman HG. Lifestyle risk factors for serrated colorectal polyps: a systematic review and meta-analysis. Gastroenterology. 2017 Jan;152(1):92-104.
• Higher risk of colorectal cancer-specific mortality among people who are obese before diagnosis compared to people of normal weight in a large meta-analysis of 16 observational studies⁸⁸Lee J, Meyerhardt JA, Giovannucci E, Jeon JY. Association between body mass index and prognosis of colorectal cancer: a meta-analysis of prospective cohort studies. PLoS One. 2015 Mar 26;10(3):e0120706.

Esophageal cancer

Good evidence of higher risk of esophageal squamous cell carcinomas but not adenocarcinomas among people with higher body mass index

Good evidence of slightly higher risk of Barrett’s esophagus—a risk factor for esophageal cancer—among people with the highest BMIs

• Higher risk of esophageal squamous cell carcinomas, but lower risk of esophageal adenocarcinomas with higher body mass index (BMI) in a review of 100 meta-analysesa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies⁸⁹Castro C, Peleteiro B, Lunet N. Modifiable factors and esophageal cancer: a systematic review of published meta-analyses. Journal of Gastroenterology. 2018 Jan;53(1):37-51.

Good evidence of slightly higher risk of Barrett’s esophagus—a risk factor for esophageal cancer—among people with the highest BMIs

• 8% higher risk of Barrett’s esophagus among people with the highest BMIs compared to the lowest in a very large meta-analysis of 22 observational studies⁹⁰Zhao Z, Yin Z, Zhang C. Lifestyle interventions can reduce the risk of Barrett’s esophagus: a systematic review and meta-analysis of 62 studies involving 250,157 participants. Cancer Medicine. 2021;10(15):5297-5320.

Gallbladder cancer: good evidence of moderately higher risk of gallbladder cancer among people with excess body weight

• 24% higher risk of gallbladder cancer with higher body weight in a very large meta-analysis of 19 observational studies⁹¹Campbell PT, Newton CC et al. Body size indicators and risk of gallbladder cancer: pooled analysis of individual-level data from 19 prospective cohort studies. Cancer Epidemiology, Biomarkers & Prevention. 2017 Apr;26(4):597-606.

• 6% increased risk of ovarian cancer with each 5 BMI units, such as a BMI change from 25 to 30, of excess weight in a large meta-analysesa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 25 observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies⁹²Continuous Update Project. Diet, Nutrition, Physical Activity and Ovarian Cancer. World Cancer Research Fund International. Revised 2018. Viewed September 22, 2021.

• Moderately higher risk of pancreatic cancer mortality among people without cancer at baseline with higher body mass index (BMI) during early adulthood, and slightly higher risk with higher waist-to-hip ratio or waist circumference in a very large pooled analysis of 20 observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies⁹³Genkinger JM, Kitahara CM et al. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Annals of Oncology. 2015 Nov;26(11):2257-66.

• 94% higher risk of recurrence risk after prostatectomy with weight gain after a prostate cancer diagnosis in a large observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods study⁹⁴Joshu CE, Mondul AM et al. Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prevention Research (Philadelphia, Pa.). 2011 Apr;4(4):544-51.
• Limited evidence that excess body weight is associated with an increased risk for aggressive prostate cancer.⁹⁵Lauby-Secretan B, Scoccianti C et al; International Agency for Research on Cancer Handbook Working Group. Body fatness and cancer–viewpoint of the IARC Working Group. New England Journal of Medicine. 2016 Aug 25;375(8):794-8.

• 35% higher risk of thyroid cancer among people with high body mass index (BMI) in a meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 42 observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies⁹⁶Yin DT, He H et al. The association between thyroid cancer and insulin resistance, metabolic syndrome and its components: a systematic review and meta-analysis. International Journal of Surgery. 2018 Sep;57:66-75.

• Lower risk of cancer as a whole and of breast, colorectal, kidney, esophageal, ovarian, liver, and gallbladder cancers among people with higher adherence to World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations regarding diet, physical activity, and body weight compared to lower adherence in a very large observational study⁹⁷Malcomson FC, Parra-Soto S et al. Adherence to the 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) Cancer Prevention Recommendations and risk of 14 lifestyle-related cancers in the UK Biobank prospective cohort study. BMC Medicine. 2023 Nov 28;21(1):407.